Tech at Polsky
Inventor(s):
Engineered TadA deaminase via directed evolution to produce CRISPR cytosine base editors that precisely convert target cytosines to thymines in specific DNA contexts with high efficiency and minimal off-target effects
The Unmet Need: Gene editing tools that exclusively acting on cytosine at levels comparable to naturally occurring deaminases reducing off-target effects
Despite successes, current base editors suffer from bystander edits, off-target activity, and context dependence. Many cytosine base editors indiscriminately deaminate all cytosines within a 4–5 nucleotide window, leading to unwanted mutations that complicate downstream analyses or therapeutic applications. Editing efficiency often varies dramatically with local sequence context, leaving many disease-relevant loci inaccessible, while off-target RNA and DNA deamination pose additional safety risks. The inability to selectively modify a single nucleotide among adjacent identical bases further limits precision and restricts the correction of pathogenic point mutations.
The Proposed Solution: Targeted strategy for altering the substrate specificity of E. coli TadA enabling the conversion of a dual adenine and cytosine deaminase into variants that selectively deaminate cytosine
Existing cytosine base editors often suffer from bystander edits, limited single-nucleotide selectivity and variable efficiency across sequence contexts. By contrast, the evolved TadA-derived editors achieve precise conversion of a single cytosine among multiple. A panel of 16 NCN-preferring variants exhibits high editing efficiency (up to 68%) with minimal adenine editing (<0.4%) and broad correction of disease-associated sites offering unparalleled precision and expanded target scope for research and therapeutic applications.
Precise C-to-T editing in specific NCN contexts, eliminating bystander and off-target A deamination
High on-target efficiencies (up to ~68.7%) across a panel of 16 context-specific deaminases
Minimal off-target activity in DNA and RNA (<0.4% unwanted A editing and reduced genome-wide/off-target edits)
Enables precise correction of clinically relevant mutations (e.g., KRAS G12D, TP53 R248Q) in human cells
Modular, evolvable platform for tailoring deaminases to any NCN context via bacterial selection
June 12, 2025
Proof of concept
Patent Pending
Licensing,Co-development
Weixin Tang
Published 6/12/2025
Reference ID 24-T-089
Have Questions?
Contact Michael Hinton, Senior Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.